Retro Biosciences focuses on extending human healthspan by roughly 10 years through drug discovery and cell-reprogramming technologies. The company has trained a model with OpenAI to convert ordinary cells into stem cells and plans to advance programs into clinical trials, including work targeting Alzheimer's disease. CEO Joe Betts-LaCroix has articulated an accelerated timeline to discover and develop a drug within the 2020s. Financially, Retro raised a $180 million seed round funded entirely by Sam Altman and is now pursuing a $1 billion Series A in which Altman is participating. Retro's emergence places it among well-funded longevity efforts backed by prominent tech investors.

Total raised

$180M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2023